Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: HeyRainier who wrote (5917)	3/15/2002 5:24:09 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

Research pixykine and the like. IMO, IMNX was saved by non-scientists. But..... to the new story, CRXA. I can't conceive of any rationale for many of the early projects at CRXA, particularly the adjuvant programs. When they failed, they purchased another crappy (IMO) adjuvant program when they bought Ribi. So..... followed IMNX very closely early in history. Followed RIBI very closely early in history. Followed CRXA very closely since inception. My background is sufficient in the immunogenicity (or lack thereof) of spontaneous and induced cancers, and I believe that CRXA is largely based on BS dogma. >> analyst Andrew Heyward << Analysts come and go. Very few get it right while they're here. >> Quite a broad pipeline << Broad doesn't count when it's enriched in garbage.